Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.79 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.79 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.79 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250991 | 1.00 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15087556 | 0.92 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3439276 | 0.91 | GUCY1B2 (0.72) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3437255 | 0.91 | GUCY1B2 (0.72) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18405244 | 0.91 | GUCY1B2 (0.72) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL10269507 | 0.91 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3437146 | 0.91 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15069463 | 0.90 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436889 | 0.90 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17307870 | 0.89 | GUCY1B2 (0.64) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221665-A | Methods and intermediates for preparing soluble guanylate cyclase stimulators | 赛克里翁治疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118184645-A | Methods and intermediates for preparing soluble guanylate cyclase stimulators | 赛克里翁治疗有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-111902410-B | Methods and intermediates for preparing soluble guanylate cyclase stimulators | 赛克里翁治疗有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116942616-A | Solid dispersion comprising sGC stimulators | 赛克里翁治疗有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-112105358-B | Non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscle or neuromuscular diseases | 拜耳公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116637077-A | Solid dispersion comprising sGC stimulators | 赛克里翁治疗有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116637076-A | Solid dispersion comprising sGC stimulators | 赛克里翁治疗有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-109563086-B | Process for preparing soluble guanylate cyclase stimulators | 赛克里翁治疗有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |